Safety and Efficacy of Bupivacaine HCl Collagen-Matrix Implant (INL-001) in Open Inguinal Hernia Repair: Results from Two Randomized Controlled Trials

Vic Velanovich, Paul Rider, Kenneth Deck, Harold S Minkowitz, David Leiman, Nigel Jones, Gwendolyn Niebler, Vic Velanovich, Paul Rider, Kenneth Deck, Harold S Minkowitz, David Leiman, Nigel Jones, Gwendolyn Niebler

Abstract

Introduction: Surgical site infiltration with bupivacaine results in short-lived analgesia. The MATRIX-1 and MATRIX-2 studies examined the efficacy and safety of the bioresorbable bupivacaine HCl collagen-matrix implant (INL-001) for postsurgical pain after open inguinal hernia repair. INL-001, designed to provide early and extended delivery of bupivacaine, provides prolonged duration of perioperative analgesia.

Methods: In two phase 3 double-blind studies [MATRIX-1 (ClinicalTrials.gov identifier, NCT02523599) and MATRIX-2 (ClinicalTrials.gov identifier, NCT02525133)], patients undergoing open tension-free mesh inguinal hernia repair were randomized to receive 300-mg bupivacaine (three INL-001 100-mg bupivacaine HCl collagen-matrix implants) (MATRIX-1 n = 204; MATRIX-2 n = 213) or three placebo collagen-matrix implants (MATRIX-1 n = 101; MATRIX-2 n = 106) during surgery. Postsurgical medication included scheduled acetaminophen and as-needed opioids.

Results: Patients who received INL-001 in both studies reported statistically significantly lower pain intensity (P ≤ 0.004; primary end point) and opioid analgesic use (P < 0.0001) through 24-h post-surgery versus those who received a placebo collagen-matrix. Patients who received INL-001 reported lower pain intensity through 72 h (P = 0.0441) for the two pooled studies. In both studies, more of the patients (28-42%) who received INL-001 used no opioid medication 0-24, 0-48, and 0-72 h post-surgery versus those who received a placebo collagen-matrix (12-22%). Among patients who needed opioid medication, patients receiving INL-001 used fewer opioids than those who received a placebo collagen-matrix through 24 h in both studies (P < 0.0001) and through 48 h in MATRIX-2 (P = 0.0003). Most adverse events were mild or moderate, without evidence of bupivacaine toxicity or deleterious effects on wound healing.

Conclusion: These findings indicate that INL-001 results in post-inguinal hernia repair analgesia that is temporally aligned with the period of maximal postsurgical pain and may reduce the need for opioids while offering a favorable safety profile.

Trial registration: ClinicalTrials.gov identifiers, NCT02523599; NCT02525133.

Funding: Innocoll Pharmaceuticals. Plain language summary available for this article.

Keywords: Bupivacaine HCl collagen-matrix implant; INL-001; Postoperative pain intensity; Rescue opioid analgesia.

Figures

Fig. 1
Fig. 1
Patient disposition for MATRIX-1 and MATRIX-2. aOne patient was randomized to INL-001 but not treated because of investigator decision. bOne patient was randomized to INL-001 but received placebo; the patient included in INL-001 mITT population and placebo safety population. ITT intent-to-treat, mITT modified intent-to-treat
Fig. 2
Fig. 2
Patients who did not use rescue opioid analgesia (mITT population). mITT modified intent-to-treat

References

    1. Morrison RS, Magaziner J, McLaughlin MA, Orosz G, Silberzweig SB, Koval KJ, et al. The impact of post-operative pain on outcomes following hip fracture. Pain. 2003;103(3):303–311. doi: 10.1016/S0304-3959(02)00458-X.
    1. Robinson KP, Wagstaff KJ, Sanghera S, Kerry RM. Postoperative pain following primary lower limb arthroplasty and enhanced recovery pathway. Ann R Coll Surg Engl. 2014;96(4):302–306. doi: 10.1308/003588414X13946184900525.
    1. Stephens J, Laskin B, Pashos C, Peña B, Wong J. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Rheumatology (Oxford) 2003;42(suppl 3):iii40–iii52.
    1. Beauregard L, Pomp A, Choinière M. Severity and impact of pain after day-surgery. Can J Anaesth. 1998;45(4):304–311. doi: 10.1007/BF03012019.
    1. Gramke HF, de Rijke JM, van Kleef M, Raps F, Kessels AG, Peters ML, et al. The prevalence of postoperative pain in a cross-sectional group of patients after day-case surgery in a university hospital. Clin J Pain. 2007;23(6):543–548. doi: 10.1097/AJP.0b013e318074c970.
    1. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 suppl):S105–S120.
    1. Shaffer EE, Pham A, Woldman RL, Spiegelman A, Strassels SA, Wan GJ, et al. Estimating the effect of intravenous acetaminophen for postoperative pain management on length of stay and inpatient hospital costs. Adv Ther. 2017;33(12):2211–2228. doi: 10.1007/s12325-016-0438-y.
    1. Oderda GM, Said Q, Evans RS, Stoddard GJ, Lloyd J, Jackson K, et al. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother. 2007;41(3):400–406. doi: 10.1345/aph.1H386.
    1. Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use—United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66(10):265–269. doi: 10.15585/mmwr.mm6610a1.
    1. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624–1645. doi: 10.1001/jama.2016.1464.
    1. Devin CJ, McGirt MJ. Best evidence in multimodal pain management in spine surgery and means of assessing postoperative pain and functional outcomes. J Clin Neurosci. 2015;22(6):930–938. doi: 10.1016/j.jocn.2015.01.003.
    1. Fawcett WJ, Baldini G. Optimal analgesia during major open and laparoscopic abdominal surgery. Anesthesiol Clin. 2015;33(1):65–78. doi: 10.1016/j.anclin.2014.11.005.
    1. Babst CR, Gilling BN. Bupivacaine: a review. Anesth Prog. 1978;25(3):87–91.
    1. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131–157. doi: 10.1016/j.jpain.2015.12.008.
    1. Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003;97(2):534–540. doi: 10.1213/01.ANE.0000068822.10113.9E.
    1. Tong YC, Kaye AD, Urman RD. Liposomal bupivacaine and clinical outcomes. Best Pract Res Clin Anaesthesiol. 2014;28(1):15–27. doi: 10.1016/j.bpa.2014.02.001.
    1. Gudgeon DH. Paracervical block with bupivacaine 0.25 per cent. Br Med J. 1968;2(5602):403. doi: 10.1136/bmj.2.5602.403.
    1. McGee DL. Local and topical anesthesia. In: Roberts JR, Hedges JR, editors. Roberts and Hedges’ clinical procedures in emergency medicine. 5. Philadelphia: Saunders Elsevier; 2010. p. 481.
    1. Svensson I, Sjöström B, Haljamäe H. Assessment of pain experiences after elective surgery. J Pain Symptom Manag. 2000;20(3):193–201. doi: 10.1016/S0885-3924(00)00174-3.
    1. Gadsden J. Local anesthetics: clinical pharmacology and rational selection. NYSORA website. 2017. . Accessed 5 Dec 2017.
    1. Goyal R, Shukla RN. Local anesthetic systemic toxicity (LAST)—should we not be concerned? Med J Armed Forces India. 2012;68(4):371–375. doi: 10.1016/j.mjafi.2012.02.011.
    1. Gupta A. Wound infiltration with local anaesthetics in ambulatory surgery. Curr Opin Anaesthesiol. 2010;23(6):708–713. doi: 10.1097/ACO.0b013e32833f0dd7.
    1. Marcaine (bupivacaine hydrochloride injection, USP) [prescribing information]. Lake Forest, IL: Hospira, Inc. 2011. . Accessed 04 Sept 2018.
    1. Whiteman A, Bajaj S, Hasan M. Novel techniques of local anaesthetic infiltration. Contin Educ Anaesth Crit Care Pain. 2011;11(5):167–171. doi: 10.1093/bjaceaccp/mkr026.
    1. Dewaele S, Santos AC. Toxicity of local anesthetics. NYSORA website. 2018. . Accessed 20 Feb 2018.
    1. Cusack SL, Jaros M, Kuss M, Minkowitz HS, Winkle P, Hemsen L. Clinical evaluation of XaraColl®, a bupivacaine-collagen implant, for postoperative analgesia in two multicenter, randomized, double-blind, placebo-controlled pilot studies. J Pain Res. 2012;5:217–225. doi: 10.2147/JPR.S33453.
    1. Cusack SL, Minkowitz HS, Kuss M, Jaros M, Hemsen L. A randomized, multicenter, pilot study comparing the efficacy and safety of a bupivacaine-collagen implant (XaraColl®) with the ON-Q* PainBuster®) Post-op Pain Relief System following open gynecological surgery. J Pain Res. 2012;5:453–461. doi: 10.2147/JPR.S37310.
    1. Hemsen L, Cusack SL, Minkowitz HS, Kuss ME. A feasibility study to investigate the use of a bupivacaine-collagen implant (XaraColl) for postoperative analgesia following laparoscopic surgery. J Pain Res. 2013;6:79–85. doi: 10.2147/JPR.S40158.
    1. Cusack SL, Reginald P, Hemsen L, Umerah E. The pharmacokinetics and safety of an intraoperative bupivacaine-collagen implant (XaraColl®) for postoperative analgesia in women following total abdominal hysterectomy. J Pain Res. 2013;6:151–159. doi: 10.2147/JPR.S40976.
    1. Huber A, Badylak SF. Biologic scaffolds for regenerative medicine. In: Atala A, Lanza R, Thomson JA, Nerem R, editors. Principles of regenerative medicine. 2. Boston: Academic Press; 2011. pp. 623–635.
    1. Delgado LM, Bayon Y, Pandit A, Zeugolis DI. To cross-link or not to cross-link? Cross-linking associated foreign body response of collagen-based devices. Tissue Eng Part B Rev. 2015;21(3):298–313. doi: 10.1089/ten.teb.2014.0290.
    1. Anselme K, Bacques C, Charriere G, Hartmann DJ, Herbage D, Garrone R. Tissue reaction to subcutaneous implantation of a collagen sponge. A histological, ultrastructural, and immunological study. J Biomed Mater Res. 1990;24(6):689–703. doi: 10.1002/jbm.820240605.
    1. Burke KE, Naughton G, Waldo E, Cassai N. Bovine collagen implant: histologic chronology in pig dermis. J Dermatol Surg Oncol. 1983;9(11):889–895. doi: 10.1111/j.1524-4725.1983.tb01036.x.
    1. Leiman D, Niebler G, Minkowitz H. Pharmacokinetics and safety of the bupivacaine collagen-matrix implant (INL-001) compared to liquid bupivacaine infiltration after open inguinal hernia repair [abstract]. Presented at World Congress on Regional Anesthesia & Pain Medicine; April 19–21, 2018; New York, New York.
    1. Knudsen K, Beckman Suurküla M, Blomberg S, Sjövall J, Edvardsson N. Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth. 1997;78(5):507–514. doi: 10.1093/bja/78.5.507.
    1. Brummett CM, Waljee JF, Goesling J, Moser S, Lin P, Englesbe MJ, et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg. 2017;152(6):e170504. doi: 10.1001/jamasurg.2017.0504.
    1. Franneby U, Sandblom G, Nyren O, Nordin P, Gunnarsson U. Self-reported adverse events after groin hernia repair, a study based on a national register. Value Health. 2008;11(5):927–932. doi: 10.1111/j.1524-4733.2008.00330.x.
    1. Sanchez-Manuel FJ, Seco-Gil JL. Antibiotic prophylaxis for hernia repair. Cochrane Database Syst Rev. 2003;2:CD003769.
    1. Fitzgibbons RJ, Jr, Giobbie-Hurder A, Gibbs JO, Dunlop DD, Reda DJ, McCarthy M, Jr, et al. Watchful waiting vs repair of inguinal hernia in minimally symptomatic men: a randomized clinical trial. JAMA. 2006;295(3):285–292. doi: 10.1001/jama.295.3.285.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel